Online Inquiry
Small Molecule Drug Development for Prostate Cancer
Among the many therapeutic options, many small molecule drugs have been proven to have therapeutic effects on prostate cancer. With a deep understanding of the unique challenges associated with prostate diseases, Alfa Cytology provides one-stop small molecule drug development services for prostate cancer.
Introduction to Small Molecule Drug
Globally, prostate cancer ranks as the second most prevalent cancer among men, posing a serious threat to human health, with small molecule drugs being one of the keys to meeting this challenge. Small molecule drugs are synthetic medicinal chemicals, and they have relatively simple structures, customizable to meet specific therapeutic goals. These drugs provide more personalized and effective therapeutic options by targeting specific molecular targets of tumor cells, such as the androgen receptor (AR) signaling pathway, PARP and microtubule.
Fig. 1 Small molecule drugs approved for prostate cancer treatment. (Zhang J Y, et al. 2023)
Advantages of Small Molecule Drug
In the complex therapy field of prostate cancer, small molecule drugs are gradually becoming an indispensable part of the therapy strategy due to their precise targeting capabilities and innovative therapeutic mechanisms.
Targeted Therapy
Small molecule drugs such as AR antagonists (e.g., bicalutamide, enzalutamide, and apalutamide) inhibit the growth of prostate cancer cells by competitively binding to the ligand-binding domain of the androgen receptor, preventing androgens from binding to the receptor.
Precision Therapy
With a deeper understanding of the molecular mechanisms of prostate cancer, small molecule drugs can be directed at specific molecular targets, realizing precision medicine, improving therapeutic efficacy and reducing unnecessary side effects.
Small Molecule Drug Development for Prostate Cancer
The latest research progress shows that small molecule drugs show significant therapeutic potential in some key areas, including targeting new molecular targets, new strategies to combat drug resistance, and epigenetic-based drug development, especially targeting the androgen receptor (AR) and its variants.
| Name | Target | Phase | Company | Country |
| H001 | AR | IND-enabling | Halda Therapeutics | USA |
| Proxalutamide | AR | Phase I | Kintor Pharmaceutical Limited | China |
| X-Synergy | AR | Phase I | Kanpu Biopharma | China |
| TAS-3681 | AR | Phase I | Taiho Pharmaceutical | Japan |
| KZR-261 | AR | Phase I/II | TRACON Pharmaceuticals | USA |
| TRC253 | AR | Phase I/IIA | TRACON Pharmaceuticals | USA |
| Darolutamide | AR | Market Approval | Bayer AG & Orion Corporation | Germany & Finland |
Our Services
At Alfa Cytology, we strive to develop safer, more effective, and more personalized therapies by constantly advancing the research and development of small molecule drugs. As one of the world's leading small molecule drug developers, we have extensive experience in the field.
Workflow of Small Molecule Drug Development
Alfa Cytology provides one-stop drug development services tailored specifically for prostate cancer. We offer a full suite of services, including drug discovery, efficacy assessment, DMPK & ADME studies, and safety evaluations.
TARGET ID
AND VALIDATION
HIT ID AND OPTIMIZATION
LEAD
OPTIMIZATION CANDIDATE SELECTION CANDIDATE PROFILING
OPTIMIZATION CANDIDATE SELECTION CANDIDATE PROFILING
- Genetics
- Molecular biology
- Cell-based studies
- Animals studies
- Screening
- Hit pharmacology profiling
- Medicinal chemistry
- In vitro ADME
- Physiochemical properties
- Medicinal chemistry
- Pharmacology
- In vitro and in vivo ADME
- Physiochemical properties
- Initial animals efficacy studies
- Higher species PK
- Animals efficacy
- Preliminary rodent toxicology
- Preliminary toxicology
- Version and form screening
- Formulation development
- Version and form selection
- Formulation development
- Rodent and higher species toxicology
- Definitive
- IND preparation
Our Advantages
We are committed to providing efficient, innovative and reliable development solutions by leveraging our in-depth professional knowledge, adopting cutting-edge technologies, and enforcing strict quality control standards.
Professional Knowledge
Cutting-Edge Technologies
Quality Control
If you are looking to develop innovative small molecule drugs for prostate cancer, our expert team can provide comprehensive support. By partnering with us, you'll receive personalized consulting services and efficient project advancement. If you are interested in our services, please don't hesitate to contact us for further information and pricing details.
Reference
- Zhang J Y, et al. Synthesis and clinical application of small-molecule drugs approved to treat prostatic cancer. Eur J Med Chem. 2023, 262: 115925.
For research use only.